Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of a single dose of E6130 in Japanese healthy adult male participants.


Clinical Trial Description

This study consists of 8 cohorts, Cohorts 1 to 8. Cohorts 1 to 7 are designed as a single-center, single dose, placebo-controlled, randomized, ascending dose, double-blind study. Cohort 8 is designed as a single-center, single dose, randomized, open-label, two-group, two-period crossover study. Cohort 8 will be initiated after Cohorts 1 to 7 are completed. ;


Study Design


Related Conditions & MeSH terms

  • Japanese Healthy Adult Male Participants

NCT number NCT02902978
Study type Interventional
Source Eisai Inc.
Contact
Status Completed
Phase Phase 1
Start date September 26, 2016
Completion date August 17, 2017

See also
  Status Clinical Trial Phase
Completed NCT03042299 - A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation Phase 1
Completed NCT03237156 - Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants Phase 1